First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1-Reference-Cited by-同舟云学术

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Published:2021-04 Issue:4 Volume:16 Page:665-676
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Reck Martin,Ciuleanu Tudor-Eliade,Lee Jong-Seok,Schenker Michael,Audigier-Valette Clarisse,Zurawski Bogdan,Linardou Helena,Otterson Gregory A.,Salman Pamela,Nishio Makoto,de la Mora Jimenez Emmanuel,Lesniewski-Kmak Krysztof,Albert István,Ahmed Samreen,Syrigos Konstantinos,Penrod John R.,Yuan Yong,Blum Steven I.,Nathan Faith E.,Sun Xiaowu,Moreno-Koehler Alejandro,Taylor Fiona,O'Byrne Kenneth John

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Survivorship in non-small cell lung cancer: challenges faced and steps forward;Vijayvergia;J Natl Compr Canc Netw,2015

2. An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients;Gralla;J Thorac Oncol,2014

3. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study;Iyer;Support Care Cancer,2014

4. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany;Iyer;Lung Cancer,2013

5. Immuno-oncology—the new paradigm of lung cancer treatment;Dawe;Curr Oncol,2020

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

2. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities;Signal Transduction and Targeted Therapy;2024-05-22

3. Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer;FUTURE ONCOL;2024

4. Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications;Advances in Cancer Biology - Metastasis;2023-10

5. The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective;Frontiers in Immunology;2023-09-11